Highlights

  • Emyria opened its first New South Wales clinic, bringing the Empax Clinic Network to four states.
  • Quarterly revenue was about $1.42 million, compared with $0.47 million a year earlier.
  • First approvals for eligible Department of Veterans' Affairs patients were received after quarter end.
  • Emyria was invited to speak at a US FDA public hearing on psychedelic medicines.

Emyria Limited (ASX:EMD) has released its quarterly activities and cash flow report for the period ended 30 September 2026. The company described the quarter as one of operational execution, highlighted by the opening of its first New South Wales clinic, growing revenue and progress on international opportunities.

Empax Clinic Network Expands to Four States

Emyria's first Empax clinic in New South Wales opened on schedule, serving Western Sydney and regional NSW. Initial patients have been funded under the state's workers' compensation scheme. The opening brings the Empax network to four states, with national treatment beds increasing from 14 to 18, supporting up to 90 dosing sessions per week.

In Victoria, the Mornington Peninsula clinic will onboard a second Authorised Prescriber in Q4 CY2026. In Perth, two additional Authorised Prescribers were onboarded and 15 more therapists were trained. In Brisbane, three new Authorised Prescribers began onboarding late in the quarter, with dosing consistency expected to improve over the coming months.

Veterans' Affairs and Global Partnerships

After the quarter, Emyria received its first approvals for eligible Department of Veterans' Affairs (DVA) patient applications. More than 40 DVA referrals have been received nationally, and the first DVA-funded treatments are being prepared.

Under the Empax Global Partnership Program, late-stage discussions are underway with an international pharmaceutical drug sponsor, which would become the second sponsor in the program if finalised. In September, the US FDA invited Emyria to speak at a public hearing on future therapeutic applications of psychedelic medicines, where Executive Chair Greg Hutchinson presented the company's real-world treatment experience. Former US Secretary of Veterans Affairs Dr David Shulkin was also appointed as a strategic advisor.

Financial Performance and Outlook

Quarterly revenue was about $1.42 million, up from $0.47 million in the September quarter of 2025. Cash receipts from customers were about $1.6 million, and the net operating cash outflow was about $2.3 million, reflecting investment in workforce readiness and medication reserves for the Sydney clinic. Cash stood at $4.745 million at 30 September 2026.

Mr Hutchinson said, "The September quarter was a defining period for Emyria." The company's priorities include starting DVA-funded treatments, growing patient numbers in Sydney, increasing utilisation across the network and pursuing US partnership opportunities.

Key Takeaways

  • The Empax Clinic Network now operates across four Australian states.
  • Revenue grew strongly compared with the same quarter last year.
  • DVA approvals open a new funding pathway for veteran patients.
  • The FDA hearing invitation and new strategic advisor support Emyria's US ambitions.